Spray Venture Partners

Spray Venture Partners is a Massachusetts-based private equity firm established in 1996 that specializes in early-stage investments in healthcare and life-science companies across the United States. The firm is dedicated to contributing both capital and expertise to emerging healthcare technology companies. By collaborating closely with clinical and technical founders, Spray Venture Partners aims to create and support companies that develop, market, and deploy innovative technologies addressing significant unmet healthcare needs. The firm focuses on sectors such as healthcare technology, diagnostic solutions, and therapeutic technologies, positioning itself as a key player in fostering advancements in the healthcare industry.

30 past transactions

Conventus Orthopaedics

Venture Round in 2013
Conventus Orthopaedics provides a range of orthopedic and sports medicine services. The physicians specialize in orthopedic surgery, reconstructive surgery, spine surgery, joint replacement, sports medicine, physical therapy, and operative care of fractures, arthritis, strains, sprains, and sports-related injuries. Conventus was formed by a team of medical professionals with the sole purpose of creating less invasive ways to treat challenging periarticular fractures. By leveraging advanced nitinol technology, the Conventus team has developed a platform technology that provides robust fixation and creates reliable repairs. The company was incorporated in 2009 and is based in Maple Grove, Minnesota.

Tryton Medical

Venture Round in 2013
Tryton Medical, Inc. is a medical device company based in Durham, North Carolina, specializing in the development and manufacturing of side branch stent systems designed to treat coronary bifurcation lesions in patients with cardiovascular diseases. Founded in 2003, the company provides its innovative Tryton Side Branch Stent System, which targets atherosclerotic lesions at bifurcation sites. Tryton Medical distributes its products through a global network of distributors and also addresses investigational needs within the United States. The company's offerings are available in several countries, including Austria, Belgium, Denmark, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the United Kingdom.

Direct Flow Medical

Venture Round in 2012
Direct Flow Medical is a medical device company specializing in the development of transcatheter aortic tissue valve prostheses aimed at treating cardiac valve insufficiency. With approximately 1.2 million individuals over the age of 65 affected by calcified aortic valves, the company addresses a significant healthcare need, as only about 150,000 of these cases receive surgical treatment annually. The company's innovative technologies focus on improving patient outcomes and minimizing complications associated with heart valve replacement. By offering repeated assessments of hemodynamic performance prior to final implantation, Direct Flow Medical enables heart surgeons to perform valve replacements through less invasive procedures, thereby enhancing the safety and effectiveness of cardiac interventions.

Solace Therapeutics

Venture Round in 2012
Solace Therapeutics, Inc. develops non-surgical office based treatments for unexpected bladder leaks in women. The company provides Vesair Bladder Control System, a non-surgical device that floats within the urinary bladder to eliminate and reduce involuntary urinary leakage. Its Vesair Bladder Control System is a non-surgical alternative to involuntary urinary leakage and a lightweight device to address the cause of stress urinary incontinence. The company was incorporated in 2002 and is based in Framingham, Massachusetts.

PneumRx

Venture Round in 2011
PneumRx, Inc. is a medical device company that specializes in developing minimally invasive treatments for patients with emphysema. Founded in 2004 and headquartered in Mountain View, California, the company is known for its RePneu Lung Volume Reduction Coil, an investigational device aimed at improving the quality of life for individuals suffering from this chronic respiratory condition. PneumRx focuses on addressing unmet medical needs in pulmonary medicine through innovative solutions.

Tryton Medical

Series D in 2010
Tryton Medical, Inc. is a medical device company based in Durham, North Carolina, specializing in the development and manufacturing of side branch stent systems designed to treat coronary bifurcation lesions in patients with cardiovascular diseases. Founded in 2003, the company provides its innovative Tryton Side Branch Stent System, which targets atherosclerotic lesions at bifurcation sites. Tryton Medical distributes its products through a global network of distributors and also addresses investigational needs within the United States. The company's offerings are available in several countries, including Austria, Belgium, Denmark, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the United Kingdom.

TearScience

Series C in 2010
TearScience, Inc. is a medical device company that engages in identifying, diagnosing, and treating meibomian gland disease (MGD), which is the cause of dry eye. The company focuses on the early detection and treatment of prevalent, chronic, and progressive MGD. It develops LipiFlow Activator, a single-use sterile device that delivers automated therapeutic energies to each meibomian gland while protecting the delicate structures of the patient’s eye; and LipiScan, a gland imager that allows eye care professionals to evaluate meibomian glands in practices. The company was formerly known as Kolis Scientific, Inc. and changed its name to TearScience, Inc. in July 2005. TearScience, Inc. was founded in 2005 and is based in Morrisville, North Carolina. As of September 6, 2017, TearScience, Inc. operates as a subsidiary of Johnson & Johnson Surgical Vision, Inc.

Barricaid

Venture Round in 2010
Intrinsic Therapeutics, Inc. develops and manufactures medical devices aimed at treating lumbar disc herniations, primarily under the trade name Barricaid. The company specializes in creating anular prostheses for partial replacement following discectomy surgery, as well as an anular closure device designed to prevent reherniations in patients with anular defects. Barricaid enables the reconstruction of weakened and ruptured spinal tissues, addressing issues related to sciatica and low back pain. Intrinsic Therapeutics serves both surgeons and patients and distributes its products across various countries, including Germany, Austria, Australia, and several others in Europe and Latin America. Founded in 2000 and based in Woburn, Massachusetts, the company also maintains offices in Oirschot, The Netherlands, and Düsseldorf, Germany.

Direct Flow Medical

Series C in 2009
Direct Flow Medical is a medical device company specializing in the development of transcatheter aortic tissue valve prostheses aimed at treating cardiac valve insufficiency. With approximately 1.2 million individuals over the age of 65 affected by calcified aortic valves, the company addresses a significant healthcare need, as only about 150,000 of these cases receive surgical treatment annually. The company's innovative technologies focus on improving patient outcomes and minimizing complications associated with heart valve replacement. By offering repeated assessments of hemodynamic performance prior to final implantation, Direct Flow Medical enables heart surgeons to perform valve replacements through less invasive procedures, thereby enhancing the safety and effectiveness of cardiac interventions.

Interlace Medical

Series C in 2009
Interlace Medical, Inc. specializes in the design and development of medical devices aimed at interventional gynecologists for office-based procedures. The company focuses on treating gynecological diseases and conditions that have traditionally required surgical intervention in an operating room setting. Among its notable products is the MyoSure hysteroscopic tissue removal system, which is specifically designed for the removal of submucosal fibroids and polyps. Through its innovative solutions, Interlace Medical seeks to enhance the efficiency and effectiveness of gynecological treatments.

Facet Solutions

Debt Financing in 2009
Facet Solutions develops surgical devices for the treatment of degenerative spinal disorders. Facet Solutions was founded on 2003 and is based in Hopkinton, Massachusetts.

Interlace Medical

Series B in 2008
Interlace Medical, Inc. specializes in the design and development of medical devices aimed at interventional gynecologists for office-based procedures. The company focuses on treating gynecological diseases and conditions that have traditionally required surgical intervention in an operating room setting. Among its notable products is the MyoSure hysteroscopic tissue removal system, which is specifically designed for the removal of submucosal fibroids and polyps. Through its innovative solutions, Interlace Medical seeks to enhance the efficiency and effectiveness of gynecological treatments.

Tryton Medical

Series C in 2008
Tryton Medical, Inc. is a medical device company based in Durham, North Carolina, specializing in the development and manufacturing of side branch stent systems designed to treat coronary bifurcation lesions in patients with cardiovascular diseases. Founded in 2003, the company provides its innovative Tryton Side Branch Stent System, which targets atherosclerotic lesions at bifurcation sites. Tryton Medical distributes its products through a global network of distributors and also addresses investigational needs within the United States. The company's offerings are available in several countries, including Austria, Belgium, Denmark, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the United Kingdom.

Direct Flow Medical

Series B in 2007
Direct Flow Medical is a medical device company specializing in the development of transcatheter aortic tissue valve prostheses aimed at treating cardiac valve insufficiency. With approximately 1.2 million individuals over the age of 65 affected by calcified aortic valves, the company addresses a significant healthcare need, as only about 150,000 of these cases receive surgical treatment annually. The company's innovative technologies focus on improving patient outcomes and minimizing complications associated with heart valve replacement. By offering repeated assessments of hemodynamic performance prior to final implantation, Direct Flow Medical enables heart surgeons to perform valve replacements through less invasive procedures, thereby enhancing the safety and effectiveness of cardiac interventions.

Barricaid

Series D in 2007
Intrinsic Therapeutics, Inc. develops and manufactures medical devices aimed at treating lumbar disc herniations, primarily under the trade name Barricaid. The company specializes in creating anular prostheses for partial replacement following discectomy surgery, as well as an anular closure device designed to prevent reherniations in patients with anular defects. Barricaid enables the reconstruction of weakened and ruptured spinal tissues, addressing issues related to sciatica and low back pain. Intrinsic Therapeutics serves both surgeons and patients and distributes its products across various countries, including Germany, Austria, Australia, and several others in Europe and Latin America. Founded in 2000 and based in Woburn, Massachusetts, the company also maintains offices in Oirschot, The Netherlands, and Düsseldorf, Germany.

Leptos Biomedical

Series C in 2007
Leptos Biomedical offers a proprietary neuromodulation therapy solution for chronic obesity. The company delivers its treatment, which involves the electrical activation of a nerve in the autonomic nervous system via a pacemaker-type device. Leptos Biomedical was founded in 2002 and is based in Fridley, Minnesota.

Interlace Medical

Series B in 2007
Interlace Medical, Inc. specializes in the design and development of medical devices aimed at interventional gynecologists for office-based procedures. The company focuses on treating gynecological diseases and conditions that have traditionally required surgical intervention in an operating room setting. Among its notable products is the MyoSure hysteroscopic tissue removal system, which is specifically designed for the removal of submucosal fibroids and polyps. Through its innovative solutions, Interlace Medical seeks to enhance the efficiency and effectiveness of gynecological treatments.

PneumRx

Series B in 2007
PneumRx, Inc. is a medical device company that specializes in developing minimally invasive treatments for patients with emphysema. Founded in 2004 and headquartered in Mountain View, California, the company is known for its RePneu Lung Volume Reduction Coil, an investigational device aimed at improving the quality of life for individuals suffering from this chronic respiratory condition. PneumRx focuses on addressing unmet medical needs in pulmonary medicine through innovative solutions.

TearScience

Series B in 2007
TearScience, Inc. is a medical device company that engages in identifying, diagnosing, and treating meibomian gland disease (MGD), which is the cause of dry eye. The company focuses on the early detection and treatment of prevalent, chronic, and progressive MGD. It develops LipiFlow Activator, a single-use sterile device that delivers automated therapeutic energies to each meibomian gland while protecting the delicate structures of the patient’s eye; and LipiScan, a gland imager that allows eye care professionals to evaluate meibomian glands in practices. The company was formerly known as Kolis Scientific, Inc. and changed its name to TearScience, Inc. in July 2005. TearScience, Inc. was founded in 2005 and is based in Morrisville, North Carolina. As of September 6, 2017, TearScience, Inc. operates as a subsidiary of Johnson & Johnson Surgical Vision, Inc.

Interlace Medical

Series A in 2006
Interlace Medical, Inc. specializes in the design and development of medical devices aimed at interventional gynecologists for office-based procedures. The company focuses on treating gynecological diseases and conditions that have traditionally required surgical intervention in an operating room setting. Among its notable products is the MyoSure hysteroscopic tissue removal system, which is specifically designed for the removal of submucosal fibroids and polyps. Through its innovative solutions, Interlace Medical seeks to enhance the efficiency and effectiveness of gynecological treatments.

Solace Therapeutics

Series B in 2006
Solace Therapeutics, Inc. develops non-surgical office based treatments for unexpected bladder leaks in women. The company provides Vesair Bladder Control System, a non-surgical device that floats within the urinary bladder to eliminate and reduce involuntary urinary leakage. Its Vesair Bladder Control System is a non-surgical alternative to involuntary urinary leakage and a lightweight device to address the cause of stress urinary incontinence. The company was incorporated in 2002 and is based in Framingham, Massachusetts.

Facet Solutions

Series B in 2005
Facet Solutions develops surgical devices for the treatment of degenerative spinal disorders. Facet Solutions was founded on 2003 and is based in Hopkinton, Massachusetts.

Direct Flow Medical

Series A in 2005
Direct Flow Medical is a medical device company specializing in the development of transcatheter aortic tissue valve prostheses aimed at treating cardiac valve insufficiency. With approximately 1.2 million individuals over the age of 65 affected by calcified aortic valves, the company addresses a significant healthcare need, as only about 150,000 of these cases receive surgical treatment annually. The company's innovative technologies focus on improving patient outcomes and minimizing complications associated with heart valve replacement. By offering repeated assessments of hemodynamic performance prior to final implantation, Direct Flow Medical enables heart surgeons to perform valve replacements through less invasive procedures, thereby enhancing the safety and effectiveness of cardiac interventions.

TearScience

Series A in 2005
TearScience, Inc. is a medical device company that engages in identifying, diagnosing, and treating meibomian gland disease (MGD), which is the cause of dry eye. The company focuses on the early detection and treatment of prevalent, chronic, and progressive MGD. It develops LipiFlow Activator, a single-use sterile device that delivers automated therapeutic energies to each meibomian gland while protecting the delicate structures of the patient’s eye; and LipiScan, a gland imager that allows eye care professionals to evaluate meibomian glands in practices. The company was formerly known as Kolis Scientific, Inc. and changed its name to TearScience, Inc. in July 2005. TearScience, Inc. was founded in 2005 and is based in Morrisville, North Carolina. As of September 6, 2017, TearScience, Inc. operates as a subsidiary of Johnson & Johnson Surgical Vision, Inc.

Facet Solutions

Series A in 2004
Facet Solutions develops surgical devices for the treatment of degenerative spinal disorders. Facet Solutions was founded on 2003 and is based in Hopkinton, Massachusetts.

Cotherix

Series C in 2003
Cotherix is a biopharmaceutical company dedicated to licensing, developing, and commercializing therapeutic products aimed at treating cardiopulmonary and other chronic diseases. The company's primary product, Ventavis, is an inhaled formulation of iloprost designed specifically for the treatment of pulmonary arterial hypertension in patients exhibiting New York Heart Association Class III or IV symptoms. Through its focus on innovative therapeutic solutions, Cotherix seeks to address critical healthcare needs within the cardiopulmonary sector.

Barricaid

Series C in 2002
Intrinsic Therapeutics, Inc. develops and manufactures medical devices aimed at treating lumbar disc herniations, primarily under the trade name Barricaid. The company specializes in creating anular prostheses for partial replacement following discectomy surgery, as well as an anular closure device designed to prevent reherniations in patients with anular defects. Barricaid enables the reconstruction of weakened and ruptured spinal tissues, addressing issues related to sciatica and low back pain. Intrinsic Therapeutics serves both surgeons and patients and distributes its products across various countries, including Germany, Austria, Australia, and several others in Europe and Latin America. Founded in 2000 and based in Woburn, Massachusetts, the company also maintains offices in Oirschot, The Netherlands, and Düsseldorf, Germany.

Confluent Surgical

Series C in 2002
Confluent Surgical develops products to address the need for surgical sealing and post-surgical adhesion prevention applications.The company provides DuraSeal, an adjunct to sutured dural repair during cranial surgeries to provide watertight closure. The company was founded in 1998 and is headquartered in Waltham, Massachusetts.

Barricaid

Series B in 2001
Intrinsic Therapeutics, Inc. develops and manufactures medical devices aimed at treating lumbar disc herniations, primarily under the trade name Barricaid. The company specializes in creating anular prostheses for partial replacement following discectomy surgery, as well as an anular closure device designed to prevent reherniations in patients with anular defects. Barricaid enables the reconstruction of weakened and ruptured spinal tissues, addressing issues related to sciatica and low back pain. Intrinsic Therapeutics serves both surgeons and patients and distributes its products across various countries, including Germany, Austria, Australia, and several others in Europe and Latin America. Founded in 2000 and based in Woburn, Massachusetts, the company also maintains offices in Oirschot, The Netherlands, and Düsseldorf, Germany.

Barricaid

Series A in 2000
Intrinsic Therapeutics, Inc. develops and manufactures medical devices aimed at treating lumbar disc herniations, primarily under the trade name Barricaid. The company specializes in creating anular prostheses for partial replacement following discectomy surgery, as well as an anular closure device designed to prevent reherniations in patients with anular defects. Barricaid enables the reconstruction of weakened and ruptured spinal tissues, addressing issues related to sciatica and low back pain. Intrinsic Therapeutics serves both surgeons and patients and distributes its products across various countries, including Germany, Austria, Australia, and several others in Europe and Latin America. Founded in 2000 and based in Woburn, Massachusetts, the company also maintains offices in Oirschot, The Netherlands, and Düsseldorf, Germany.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.